Eumovate (clobetasone butyrate) 0.05% cream with its moisturizing emollient base has better healing properties than hydrocortisone 1% cream: a study in nickel-induced contact dermatitis.
Eumovate (clobetasone butyrate) 0.05% cream with its moisturizing emollient base has better healing properties than hydrocortisone 1% cream: a study in nickel-induced contact dermatitis.
复制标题
Eumovate%20(氯倍他松%20丁酸酯)%200.05%%20cream%20with%20its%20moisturizing%20emollient%20base%20has%20better%20healing%20properties%20than%20氢化可的松%201%%20cream:%20a%20study%20in%20镍-
DOI：
10.1080/09546630152696107
复制
发表时间：
2001
期刊：
影响因子：
--
通讯作者：
R. Green
中科院分区：
文献类型：
--
作者：
A. Parneix‐Spake;P. Goustas;R. Green
背景
局部皮质类固醇的润肤剂基质，通过其保湿特性，可以是有用的治疗辅助剂。
目的
比较Eumovate商标（丁酸氯倍他松）0.05%霜剂与其润肤剂基质、1%氢化可的松霜剂和未治疗的愈合性能。
方法
一项单中心、双盲、个体内比较研究，涉及18名镍诱导接触性皮炎志愿者。在镍斑贴试验呈阳性后，将亚治疗量（10 μ l = 3 mg cm（-2））的每种处理剂每天两次，持续7天，用于4个试验部位。
结果
在主要终点方面，治疗7天后医生的总体评估显示，0.05%丁酸氯倍他松（CB）乳膏的反应明显优于1%氢化可的松（HC）乳膏（78% vs 39%，差异-0.4，95% CI -0.7至-0.1; p = 0.046）或未治疗（78% vs 28%，差异-0.5，95% CI -0.9至-0.1; p = 0.016）。CB 0.05%乳膏也显示出比其润肤剂基质更好的反应（78%对56%），尽管没有达到统计学显著性。在保湿效果方面，CB 0.05%霜剂与其润肤基质之间的经皮水分损失（TEWL）没有差异。然而，CB 0.05%乳膏处理的部位确实具有比未处理的部位（差异-8.5，95%CI-12.0至-4.86; p < 0.001）或HC 1%处理的部位（差异-7.1，95%CI-11.0至-3.4; p < 0.001）显著更低的值（即更湿润）。在皮肤漂白活性方面，如预期的，基于类固醇的霜剂比润肤剂基础霜剂实现更低的比色值。
结论
实验诱导的皮肤炎症的这些结果表明，CB 0.05%（作为Eumovate 0.05%霜剂）具有比氢化可的松1%霜剂更有效的抗炎活性和更好的保湿性质，并且这些效果部分归因于其有效的润肤剂基质。
BACKGROUND
The emollient base of a topical corticosteroid, through its moisturizing properties, can be a useful treatment adjunct.
OBJECTIVE
To compare the healing properties of Eumovate trade mark (clobetasone butyrate) 0.05% cream with its emollient base, hydrocortisone 1% cream and with no treatment.
METHODS
A single-centre, double-blind, intra-individual, comparative study that involved 18 volunteers with nickel-induced contact dermatitis. Following a positive patch test to nickel, sub-therapeutic amounts (10 micro l = 3 mg cm(-2)) of each of the treatments were applied twice daily for seven days to each of the four test sites.
RESULTS
In terms of the primary endpoint, a physician's global assessment after 7 days of treatment, clobetasone butyrate (CB) 0.05% cream showed a significantly better response than hydrocortisone (HC) 1% cream (78% vs 39%, difference -0.4, 95% CI -0.7 to -0.1; p = 0.046) or no treatment (78% vs 28%, difference -0.5, 95% CI -0.9 to -0.1; p = 0.016). CB 0.05% cream also showed a better response than its emollient base (78% vs 56%), though statistical significance was not achieved. In terms of moisturizing effects, there was no difference in transepidermal water loss (TEWL) between CB 0.05% cream and its emollient base. CB 0.05% cream treated sites did, however, have significantly lower values (i.e. were more moisturized) than untreated sites (difference -8.5, 95% CI -12.0 to -4.86; p < 0.001) or HC 1% treated sites (difference -7.1, 95% CI -11.0 to -3.4; p < 0.001). In terms of skin blanching activity, as expected the steroid-based creams achieved lower colorimetric values than the emollient base cream.
CONCLUSIONS
These results from experimentally induced skin inflammation indicate that CB 0.05% (as Eumovate 0.05% cream) has both more effective anti-inflammatory activity and better moisturizing properties than hydrocortisone 1% cream and that these effects are in part due to its efficient emollient base.